{
    "clinical_study": {
        "@rank": "82347", 
        "arm_group": [
            {
                "arm_group_label": "patisiran  (ALN-TTR02)", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Sterile Normal Saline (0.9% NaCl)", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in\n      patients with transthyretin (TTR) mediated amyloidosis"
        }, 
        "brief_title": "The Study of an Investigational Drug, ALN-TTR02, for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "TTR-mediated Amyloidosis", 
        "condition_browse": {
            "mesh_term": [
                "Amyloidosis", 
                "Polyneuropathies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female of 18 to 80 years of age (inclusive);\n\n          -  Have a diagnosis of FAP\n\n          -  Meet Neuropathy Impairment Score requirements and Karnofsky performance status\n             requirements\n\n          -  Have adequate complete blood counts and liver function tests\n\n          -  Have adequate cardiac function\n\n          -  Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV)\n\n        Exclusion Criteria:\n\n          -  Had a prior liver transplant or is planned to undergo liver transplant during the\n             study period;\n\n          -  Has untreated hypo- or hyperthyroidism;\n\n          -  Has known human immunodeficiency virus (HIV) infection;\n\n          -  Had a malignancy within 2 years, except for basal or squamous cell carcinoma of the\n             skin or carcinoma in situ of the cervix that has been successfully treated;\n\n          -  Recently received an investigational agent or device\n\n          -  Is currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acid"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01960348", 
            "org_study_id": "ALN-TTR02-004", 
            "secondary_id": "2013-002987-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "patisiran  (ALN-TTR02)", 
                "description": "administered by intravenous (IV) infusion", 
                "intervention_name": "patisiran (ALN-TTR02)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sterile Normal Saline (0.9% NaCl)", 
                "description": "administered by intravenous (IV) infusion", 
                "intervention_name": "Sterile Normal Saline (0.9% NaCl)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "RNAi therapeutic", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "La Mesa", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Le Kremlin-bicetre", 
                        "country": "France"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille Cedex", 
                        "country": "France"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "143-729"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto", 
                        "country": "Portugal"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Huelva", 
                        "country": "Spain"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Majorca", 
                        "country": "Spain"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ume\u00e5", 
                        "country": "Sweden"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "Korea, Republic of", 
                "Portugal", 
                "Spain", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ALN-TTR02 in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)", 
        "overall_contact": {
            "last_name": "Alnylam Clinical Trials Hotline. Call for Complete Site List.", 
            "phone": "617-575-7400 or 1-866-330-0326"
        }, 
        "overall_official": {
            "affiliation": "Alnylam Pharmaceuticals", 
            "last_name": "Jared Gollob", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Sweden: Medical Products Agency", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United States: Food and Drug Administration", 
                "South Korea: Ministry of Food and Drug Safety (MFDS)", 
                "Portugal: INFARMED, National Authority of Medicines and Health Products, IP"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The difference between the ALN TTR02 and placebo groups in the change from baseline of modified Neuropathy Impairment Score+7 (mNIS+7)", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01960348"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The difference between ALN-TTR02 and placebo in the change from baseline in quality of life", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "The difference between ALN-TTR02 and placebo in the change from baseline in motor function", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "The difference between ALN-TTR02 and placebo in the change from baseline in autonomic function", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "source": "Alnylam Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alnylam Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}